Model Hirano Bodies Protect against Tau-Independent and Tau-Dependent Cell Death Initiated by the Amyloid Precursor Protein Intracellular Domain

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Furgerson, Matthew ^a   Fechheimer, Marcus ^b   Furukawa, Ruth ^b  

^a University of Georgia ^*  (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN C31 FRAGMENT; AMYLOID PRECURSOR PROTEIN INTRACELLULAR DOMAIN C58; CELL PROTEIN; F ACTIN; PROTEIN FE65; PROTEIN P53; PROTEIN TIP60; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DEGENERATIVE DISEASE; GENETIC TRANSFECTION; HIRANO BODY; HUMAN; HUMAN CELL; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CASPASES; CELL DEATH; CYTOPROTECTION; ETOPOSIDE; HISTONE ACETYLTRANSFERASES; HUMANS; INCLUSION BODIES; MICE; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; TAU PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866508857     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044996     Document Type: Article

References (98)

1. Mott RT, Hulette CM, (2005) Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am 215: 755-765.
2. Gibson PH, Tomlinson BE, (1977) Numbers of Hirano bodies in the hippocampus of normal and demented people with Alzheimer's disease. J Neurol Sci 33: 199-206.
3. Schochet SS Jr, Lampert PW, Lindenberg R, (1968) Fine structure of the Pick and Hirano bodies in a case of Pick's disease. Acta Neuropathol (Berl) 11: 330-337.
4. Yamamoto T, Hirano A, (1985) Hirano bodies in the perikaryon of the Purkinje cell in a case of Alzheimer's disease. Acta Neuropathol 67: 167-169.
5. Hirano A, (1994) Hirano bodies and related neuronal inclusions. Neuropathol Appl Neurobiol 20: 3-11.
6. Mitake S, Ojika K, Hirano A, (1997) Hirano bodies and Alzheimer's disease. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 13: 10-18.
7. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, et al. (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876-8884.
8. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
9. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, et al. (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22: 1858-1867.
10. Cacucci F, Yi M, Wills TJ, Chapman P, O'Keefe J, (2008) Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. Proc Natl Acad Sci U S A 105: 7863-7868.
11. Pimplikar SW, (2009) Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 41: 1261-1268.
12. Zheng H, Koo EH, (2011) Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 6: 27.
13. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297: 353-356.
14. Marcello E, Epis R, Saraceno C, Di Luca M, (2012) Synaptic dysfunction in Alzheimer's disease. Adv Exp Med Biol 970: 573-601.
15. Koffie RM, Hyman BT, Spires-Jones TL, (2011) Alzheimer's disease: synapses gone cold. Mol Neurodeg 6: 63-72.
16. Benilova I, Karran E, De Strooper B, (2012) The toxic aß oliogmer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15: 349-357.
17. Dyrks T, Weidemann A, Multhaup G, Salbaum JM, Lemaire HG, et al. (1988) Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease. EMBO J 7: 949-957.
18. Glenner GG, Wong CW, (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890.
19. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, et al. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736.
20. Hardy J, (2006) A hundred years of Alzheimer's disease research. Neuron 52: 3-13.
21. Muller T, Meyer HE, Egensperger R, Marcus K, (2008) The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog Neurobiol 85: 393-406.
22. Beckett C, Nalivaeva NN, Belyaev ND, Turner AJ, (2012) Nuclear signalling by membrane protein intracellular domains: The AICD enigma. Cell Signal 24: 402-409.
23. Pardossi-Piquard R, Checler F, (2012) The physiology of the ß-amyloid precursor protein intracellular domain AICD. J Neurochem 120(Suppl. 1): 109-124.
24. Kosik KS, Joachim CL, Selkoe DJ, (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83: 4044-4048.
25. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, et al. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084-6089.
26. Tsuboi Y, (2009) Clinical, pathological, and genetic characteristics of frontotemporal dementia and parkinsonism linked to chromosome 17 with mutations in the MAPT and PGRN. Brain Nerve 61: 1285-1291.
27. Iqbal K, Liu F, C.-X G, Grundke-Iqbal I, (2010) Tau in Alzheimer Disease and related tauopathies. Curr Alzheimer Res 7: 656-664.
28. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754.
29. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, et al. (2010) Tau reduction prevents Abeta-induced defects in axonal transport. Science 330: 198-200.
30. Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, et al. (2011) Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic tau mutant. J Neurosci 31: 2511-2525.
31. Ogata J, Budzilovich GN, Cravioto H, (1972) A study of rod-like structures (Hirano bodies) in 240 normal and pathological brains. Acta Neuropathol 21: 61-67.
32. Fu Y, Ward J, Young HF, (1975) Unusual, rod-shaped cytoplasmic inclusions (Hirano bodies) in a cerebellar hemangioblastoma. Acta Neuropathol 31: 129-135.
33. Mori H, Tomonaga M, Baba N, Kanaya K, (1986) The structure analysis of Hirano bodies by digital processing on electron micrographs. Acta Neuropathol 71: 32-37.
34. Hirano A, Dembitzer HM, Kurland LT, Zimmerman HM, (1968) The fine structure of some intraganlionic alterations. J Neuropathol Expt Neurol 27: 167-182.
35. Galloway PG, Perry G, Kosik KS, Gambetti P, (1987) Hirano bodies contain tau protein. Brain Res 403: 337-340.
36. Laas R, Hagel C, (1994) Hirano bodies and chronic alcoholism. Neuropathol Appl Neurobiol 20: 12-21.
37. Martinez-Saez E, Gelpi E, Rey M, Ferrer I, Ribalta T, et al. (2011) Hirano body- rich subtypes of Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol.
38. Galloway PG, Perry G, Gambetti P, (1987) Hirano body filaments contain actin and actin-associated proteins. J Neuropathol Exp Neurol 46: 185-199.
39. Goldman JE, (1983) The association of actin with Hirano bodies. J Neuropathol Exp Neurol 42: 146-152.
40. Schochet SS Jr, McCormick WF, (1972) Ultrastructure of Hirano bodies. Acta Neuropathol 21: 50-60.
41. Izumiyama N, Ohtsubo K, Tachikawa T, Nakamura H, (1991) Elucidation of three-dimensional ultrastructure of Hirano bodies by the quick-freeze, deep-etch and replica method. Acta Neuropathol 81: 248-254.
42. Maselli AG, Davis R, Furukawa R, Fechheimer M, (2002) Formation of Hirano bodies in Dictyostelium and mammalian cells induced by expression of a modified form of an actin cross-linking protein. J Cell Sci 115: 1939-1952.
43. Davis RC, Furukawa R, Fechheimer M, (2008) A cell culture model for investigation of Hirano bodies. Acta Neuropathol 115: 205-217.
44. Ha S, Furukawa R, Stramiello M, Wagner JJ, Fechheimer M, (2011) Transgenic mouse model for the formation of Hirano bodies. BMC Neurosci 12: 97.
45. Munoz DG, Wang D, Greenberg BD, (1993) Hirano bodies accumulate C-terminal sequences of beta-amyloid precursor protein (beta-APP) epitopes. J Neuropathol Exp Neurol 52: 14-21.
46. Maselli AG, Furukawa R, Thomson SAM, Davis RC, Fechheimer M, (2003) Formation of Hirano bodies induced by expression of an actin cross-linking protein with a gain of function mutation. Eucaryot Cell 2: 778-787.
47. Ha S, Furukawa R, Fechheimer M, (2011) Association of AICD and Fe65 with Hirano bodies reduces transcriptional activation and initiation of apoptosis. Neurobiol Aging 32: 2287-2298.
48. Lu DC, Soriano S, Bredesen DE, Koo EH, (2003) Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem 87: 733-741.
49. Dickey CA, Eriksen J, Kamal A, Burrows F, Kasibhatla S, et al. (2005) Development of a high throughput drug screening assay for the detection of changes in tau levels - proof of concept with HSP90 inhibitors. Curr Alzheimer Res 2: 231-238.
50. Bretteville A, Ando K, Ghestem A, Loyens A, Begard S, et al. (2009) Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes. PLoS One 4: e4843.
51. Gibson PH, (1978) Light and electron microscopic observations on the relationship between Hirano bodies, neuron and glial perikarya in the human hippocampus. Acta Neuropathol (Berl) 42: 165-171.
52. Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W, (2011) Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2: e167.
53. Kinoshita A, Whelan CM, Berezovska O, Hyman BT, (2002) The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 277: 28530-28536.
54. Fath T, Eldenmüller J, Brandt R, (2002) Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J Neurosci 22: 9733-9741.
55. Eidenmüller J, Fath T, Maas T, Pool M, Sontag E, et al. (2001) Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem J 357: 759-767.
56. Cao X, Südhof TC, (2004) Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J Biol Chem 279: 24601-14611.
57. Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, et al. (2006) Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci 26: 6377-6385.
58. Tang Y, Luo J, Zhang W, Gu W, (2006) Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24: 827-839.
59. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, et al. (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24: 841-851.
60. Sykes SM, Stanek TJ, Frank A, Murphy ME, McMahon SB, (2009) Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J Biol Chem 284: 20197-20205.
61. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733-1737.
62. Niedowicz DM, Nelson PT, Murphy MP, (2011) Alzheimer's disease: Pathological mechanisms and recent insights. Curr Neuropharm 9: 674-684.
63. Karran E, Mercken M, De Strooper B, (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698-712.
64. Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ, (2001) The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem 276: 40288-40292.
65. Cupers P, Orlans I, Craessarts K, Annaert W, De Strooper B, (2001) The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurons in culture. J Neurochem 78: 1168-1178.
66. Weidemann A, Eggert S, Reinhard FBM, Vogel M, Paliga K, et al. (2002) A novel ε-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry 41: 2825-2835.
67. Ren Z, Schenk D, Basi GS, Shapiro IP, (2007) Amyloid ß-protein precursor juxtamembrain domain regulates specificty of γ-secretase-dependent cleavages. J Biol Chem 48: 35350-33560.
68. Yamasaki A, Eimer S, Okochi M, Smialowska A, Kaether C, et al. (2006) The GxGD motif of presenilin contributes to catalytic function and substrate identification of γ-secretase. J Neurosci 26: 3821-3828.
69. Zhang H, Ma Q, Zhang Y-w, Xu H, (2012) Proteolytic processing of the Alzheimer's ß-amyloid precursor protein. J Neurochen 120: 9-21.
70. Perl DP, (2010) Neuropathology of Alzheimer's disease. Mt Sinai J Med 77: 32-42.
71. Yokoo H, Oyama T, Hirato J, Sasaki A, Nakazato Y (1994) A case of Pick's disease with unusual neuronal inclusions. Acta Neuropathol (Berl) 88: 604-.
72. Passer B, Pellegrini L, Russo C, Siegel RM, Lenardo MJ, et al. (2000) Generation of an apoptotic intracellular peptide by gamma-secretase cleavage of Alzheimer's amyloid beta protein precursor. J Alzheimers Dis 2: 289-301.
73. Chang KA, Kim HS, Ha TY, Ha JW, Shin KY, et al. (2006) Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. Mol Biol Cell 26: 4327-4338.
74. Chang K-A, Suh Y-H, (2010) Possible roles of amyloid intracellular domain of amyloid precusor protein. BMB Rep 43: 656-663.
75. Borquez DA, Gonzalez-Billault C, (2012) The amyloid precursor protein intracellular domain-Fe65 multiprotein complexes: As challenge to the amyloid hypothesis for Alzheimer's disease? Int J Alzheimers Dis 2012: 353145-353155.
76. Cao X, Südhof TC, (2001) A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293: 115-120.
77. Kajiwara Y, Akram A, Katsel P, Haroutunian V, Schmeidler J, et al. (2009) FE65 binds Teashirt, inhibiting expression of the primate-specific caspase-4. PLoS One 4: e5071.
78. Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, et al. (2009) Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A 106: 18367-18372.
79. Nakayama K, Ohkawara T, Hiratochi M, Koh C-S, Nagase H, (2008) Intracellular domain of amyloid precursor protein induces neuron-specific apoptosis. Neurosci Lett 444: 127-131.
80. Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, et al. (2000) A second cytotoxic proteolytic peptide derived from amyloid ß-protein precursor. Nature Medicine 6: 397-404.
81. Lu DC, Shaked GM, Masliah E, Bredesen DE, Koo EH, (2003) Amyloid beta protein toxicity mediated by the formation of amyloid-beta protein precursor complexes. Ann Neurol 54: 781-789.
82. Ghosal K, Stathopoulos A, Pimplikar SW, (2010) APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One 5: e11866.
83. Ghosal K, Pimplikar SW (2011) Aging and excitotoxic stress exacerbate neural circuit reorganization in amyloid precursor protein intracellular domain transgenic mice. Neurobiol Aging 32: 2320 2321-2329.
84. Vogt DL, Thomas D, Galvan V, Bredesen DE, Lamb BT, et al. (2011) Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. Neurobiol Aging 32: 1725-1729.
85. Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, et al. (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA 99: 8025-8030.
86. McCarthy JV, Twomey C, Wujek P, (2009) Presenilin-dependent regulated intramembrane proteolysis and gamma-secretase activity. Cell Mol Life Sci 66: 1534-1555.
87. Ryan KA, Pimplikar SW, (2005) Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol 171: 327-335.
88. Cho JH, Johnson GV, (2004) Primed phosphylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 88: 349-358.
89. Li W, Lee VM, (2006) Characterization of two VQIXXK motifs for tau fibrillization in vitro. Biochemistry 45: 15692-15701.
90. Sengupta S, Horowitz PM, Karsten SL, Jackson GR, Geschwind DH, et al. (2006) Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry 45: 15111-15119.
91. Liu SJ, Zhang JY, Li HL, Fang ZY, Wang Q, et al. (2004) Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279: 50078-50088.
92. Shahani N, Subramaniam S, Wolf T, Tackenberg C, Brandt R, (2006) Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. Neurobiol Dis 26: 6103-6114.
93. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, et al. (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67: 953-966.
94. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, et al. (2011) Amyloid-ß/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31: 700-711.
95. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, et al. (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2: 252.
96. Fulga TA, Elson-Schwab I, Khurana V, Steinhib ML, Spires TL, et al. (2007) Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol 9: 139-148.
97. Santa-Maria I, Santpere G, MacDonald MJ, de Barreda EG, Hernandez F, et al. (2008) Coenzyme Q induces tau aggregation, tau filaments, and Hirano bodies. J Neuropathol Exp Neurol 67: 428-434.
98. Kim DH, Davis RC, Furukawa R, Fechheimer M, (2009) Autophagy contributes to degradation of Hirano bodies. Autophagy 5: 44-51.